Despite widespread use, mesalamine compounds have been reported to be unsafe in moderate to severe glucose-6-phosphate dehydrogenase (G6PD) deficiency by some Regulatory agencies and patient associations [8,9,10,11,12]. This evidence concerns the gene G6PD and G6PD deficiency.